NeoGenomics, Inc. (NEO) Reaches $22.12 After 5.00% Down Move; Mfs Multimarket Income Trust (MMT) SI Increased By 66.7%

NeoGenomics, Inc. (NASDAQ:NEO) Logo

Mfs Multimarket Income Trust (NYSE:MMT) had an increase of 66.7% in short interest. MMT’s SI was 150,700 shares in July as released by FINRA. Its up 66.7% from 90,400 shares previously. With 113,600 avg volume, 1 days are for Mfs Multimarket Income Trust (NYSE:MMT)’s short sellers to cover MMT’s short positions. The stock increased 0.69% or $0.04 during the last trading session, reaching $5.84. About 229,950 shares traded or 64.41% up from the average. MFS Multimarket Income Trust (NYSE:MMT) has risen 5.04% since July 14, 2018 and is uptrending. It has outperformed by 0.61% the S&P500.

The stock of NeoGenomics, Inc. (NASDAQ:NEO) is a huge mover today! The stock decreased 3.19% or $0.73 during the last trading session, reaching $22.12. About 506,557 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has risen 109.52% since July 14, 2018 and is uptrending. It has outperformed by 105.09% the S&P500. Some Historical NEO News: 01/05/2018 – Detailed Research: Economic Perspectives on NeoGenomics, Illinois Tool Works, Carriage Services, Gorman-Rupp, Fiesta Restaurant; 25/05/2018 – NeoGenomics to Participate In Two Upcoming Investor Conferences; 14/05/2018 – Next Century Growth Investors Exits Position in NeoGenomics; 20/03/2018 – NEOGENOMICS NAMES SHARON VIRAG CFO, CARDOZA HEAD OF PHARMA SVCS; 20/03/2018 – NEOGENOMICS INC NEO.O SAYS SHARON VIRAG APPOINTED CFO; 01/05/2018 – NeoGenomics Backs 2018 Adj EPS 15c-Adj EPS 20c; 20/03/2018 – NeoGenomics Names George Cardoza Pres of Pharma Services Division, Sharon Virag CFO; 01/05/2018 – NeoGenomics Sees 2018 Adj EPS 15c-Adj EPS 20c; 01/05/2018 – NeoGenomics 1Q Adj EPS 4c; 01/05/2018 – NeoGenomics Sees 2018 Loss/Shr 8c-Loss 13cThe move comes after 5 months negative chart setup for the $2.11 billion company. It was reported on Jul, 14 by Barchart.com. We have $21.01 PT which if reached, will make NASDAQ:NEO worth $105.60M less.

MFS Multimarket Income Trust is a closed ended fixed income mutual fund launched and managed by MFS Investment Management, Inc. The company has market cap of $378.81 million. The fund invests in the fixed income markets across the globe with greater emphasis on United States. It has a 14.46 P/E ratio. It seeks to invest in fixed income securities issued by U.S.

More notable recent MFS Multimarket Income Trust (NYSE:MMT) news were published by: Seekingalpha.com which released: “It’s Time We Talked About Modern Monetary Theory – Seeking Alpha” on July 01, 2019, also Seekingalpha.com with their article: “MFS Multimarket Income Trust declares $0.041920 dividend – Seeking Alpha” published on July 02, 2019, Businesswire.com published: “MFS Releases Closed-End Fund Income Distribution Sources for Certain Funds – Business Wire” on June 24, 2019. More interesting news about MFS Multimarket Income Trust (NYSE:MMT) were released by: Seekingalpha.com and their article: “Why Ray Dalio Is Wrong On Capitalism – Seeking Alpha” published on June 14, 2019 as well as Globenewswire.com‘s news article titled: “CN Grain Movement: Record Pace Continues NYSE:CNI – GlobeNewswire” with publication date: July 02, 2019.

Investors sentiment increased to 1.41 in Q1 2019. Its up 0.46, from 0.95 in 2018Q4. It is positive, as 6 investors sold MFS Multimarket Income Trust shares while 11 reduced holdings. 9 funds opened positions while 15 raised stakes. 11.45 million shares or 5.26% more from 10.88 million shares in 2018Q4 were reported. Dynamic Advisor Solutions Llc, a Arizona-based fund reported 72,846 shares. Park Avenue Securities Limited Liability Company has invested 0.01% of its portfolio in MFS Multimarket Income Trust (NYSE:MMT). Raymond James And Associate invested in 0% or 147,890 shares. Fifth Third Bankshares holds 2,633 shares. Landscape Capital Lc reported 378,096 shares. Stellar Cap Management Ltd Limited Liability Company, Arizona-based fund reported 15,425 shares. New York-based Two Sigma Securities Limited Liability has invested 0% in MFS Multimarket Income Trust (NYSE:MMT). Citigroup invested in 0% or 10,931 shares. Morgan Stanley has invested 0% in MFS Multimarket Income Trust (NYSE:MMT). Retail Bank Of America Corp De invested in 0% or 106,124 shares. Carroll Associate invested 0% of its portfolio in MFS Multimarket Income Trust (NYSE:MMT). Moreover, First Foundation has 0.17% invested in MFS Multimarket Income Trust (NYSE:MMT) for 514,278 shares. Regions Corp invested 0% in MFS Multimarket Income Trust (NYSE:MMT). Crow Point Ptnrs Ltd owns 0.15% invested in MFS Multimarket Income Trust (NYSE:MMT) for 153,500 shares. Sit Investment Associate stated it has 0.18% in MFS Multimarket Income Trust (NYSE:MMT).

Investors sentiment decreased to 1.31 in Q1 2019. Its down 0.64, from 1.95 in 2018Q4. It turned negative, as 35 investors sold NeoGenomics, Inc. shares while 60 reduced holdings. 62 funds opened positions while 62 raised stakes. 75.90 million shares or 10.75% more from 68.54 million shares in 2018Q4 were reported. Ranger Ltd Partnership holds 1.79% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 1.21 million shares. Raymond James And Assoc holds 42,572 shares. Fairpointe Ltd Liability Com invested in 0.14% or 210,807 shares. First Tru Advsrs Lp has invested 0.01% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Usa Fin Portformulas owns 12,880 shares or 0.17% of their US portfolio. Driehaus Mngmt Ltd Liability Co holds 0.58% or 749,450 shares. Rmb Limited Co holds 0.09% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 178,376 shares. Sumitomo Mitsui Incorporated, a Japan-based fund reported 39,073 shares. Invesco Ltd invested 0.01% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Franklin holds 0.02% or 1.49M shares. Tci Wealth Advsrs invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Rhumbline Advisers invested 0.01% in NeoGenomics, Inc. (NASDAQ:NEO). Moreover, American Grp has 0% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 63,472 shares. 11,500 were accumulated by Fifth Third Bancorporation. 33,730 are owned by White Pine Capital Limited Company.

Among 3 analysts covering NeoGenomics (NASDAQ:NEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NeoGenomics had 4 analyst reports since February 20, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, March 12 by First Analysis. On Wednesday, February 20 the stock rating was maintained by Stephens with “Buy”. As per Wednesday, February 20, the company rating was maintained by Needham.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $2.11 billion. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It has a 351.11 P/E ratio. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

NeoGenomics, Inc. (NASDAQ:NEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.